Precision radiation combo aims to tame High-Risk prostate cancer

NCT ID NCT04465500

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of hormone therapy, external beam radiation, and MRI-guided internal radiation implants for men with unfavorable-intermediate to very high-risk prostate cancer. The goal is to see if this precise approach causes fewer urinary side effects than standard treatments. Sixty participants will be followed for outcomes like cancer control, quality of life, and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Combination of external beam radiation therapy (EBRT), MRI-guided high dose-rate (HDR) brachytherapy, and androgen deprivation therapy (ADT)
What this could lead to
If successful, this approach could offer a more precise radiation treatment for high-risk prostate cancer with fewer severe side effects.
What could go wrong
This is a small, single-center phase 2 trial with only 60 participants, so results may not apply broadly. The combination therapy also carries risks of urinary, bowel, and sexual side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Virginia

    Charlottesville, Virginia, 22908, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.